Inflammatory Markers and Cognitive Performance in Patients With Schizophrenia Treated With Lurasidone

被引：0
作者：
Miller, Brian [1 ]
Pikalov, Andrei [1 ]
Siu, Cynthia [1 ]
Tocco, Michael [1 ]
Tsai, Joyce [1 ]
Harvey, Philip [1 ]
Loebel, Antony [1 ]
机构：
[1] Sunov Pharmaceut Inc, Ft Lee, NJ USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2017年 / 42卷
关键词：
Inflammatory Markers; Cognitive Functioning; Lurasidone; Lipids; Schizophrenia; Functional Capacity; Antipsychotic Treatment;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
W172
引用
收藏
页码：S585 / S585
页数：1
相关论文
共 50 条
  • [41] Autistic symptoms predict social cognitive performance in patients with schizophrenia
    Deste, Giacomo
    Vita, Antonio
    Penn, David L.
    Pinkham, Amy E.
    Nibbio, Gabriele
    Harvey, Philip D.
    SCHIZOPHRENIA RESEARCH, 2020, 215 : 113 - 119
  • [42] Immune markers of social cognitive bias in schizophrenia
    Dunne, Patrick W.
    Roberts, David L.
    Quinones, Marlon P.
    Velligan, Dawn I.
    Paredes, Madelaine
    Walss-Bass, Consuelo
    PSYCHIATRY RESEARCH, 2017, 251 : 319 - 324
  • [43] Lurasidone in the treatment of schizophrenia: Results of a double-blind, placebo-controlled trial in Asian patients
    Higuchi, Teruhiko
    Ishigooka, Jun
    Iyo, Masaomi
    Yeh, Chin-Bin
    Ebenezer, Esther Gunaseli
    Liang, Kuei Yu
    Lee, Jung Sik
    Lee, Sang Yeol
    Lin, Shih Ku
    Yoon, Bo-Hyun
    Nakamura, Masatoshi
    Hagi, Katsuhiko
    Sato, Takayuki
    ASIA-PACIFIC PSYCHIATRY, 2019, 11 (02)
  • [44] Subjective cognitive complaints and relations to objective cognitive performance among Lebanese patients with schizophrenia
    Haddad, Chadia
    Salameh, Pascale
    Sacre, Hala
    Polin, Clement
    Clement, Jean-Pierre
    Calvet, Benjamin
    BMC PSYCHIATRY, 2021, 21 (01)
  • [45] Subjective cognitive complaints and relations to objective cognitive performance among Lebanese patients with schizophrenia
    Chadia Haddad
    Pascale Salameh
    Hala Sacre
    Clément Polin
    Jean-Pierre Clément
    Benjamin Calvet
    BMC Psychiatry, 21
  • [46] Rosiglitazone and cognitive function in clozapine-treated patients with schizophrenia: A pilot study
    Yi, Zhenghui
    Fan, Xiaoduo
    Wang, JiJun
    Liu, Dengtang
    Freudenreich, Oliver
    Goff, Donald
    Henderson, David C.
    PSYCHIATRY RESEARCH, 2012, 200 (2-3) : 79 - 82
  • [47] Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study
    Iyo, Masaomi
    Ishigooka, Jun
    Nakamura, Masatoshi
    Sakaguchi, Reiko
    Okamoto, Keisuke
    Mao, Yongcai
    Tsai, Joyce
    Fitzgerald, Alison
    Takai, Kentaro
    Higuchi, Teruhiko
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2021, 17 : 2683 - 2695
  • [48] Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia
    Meyer, Jonathan M.
    Mao, Yongcai
    Pikalov, Andrei
    Cucchiaro, Josephine
    Loebel, Antony
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2015, 30 (06) : 342 - 350
  • [49] Adherence and Cognitive Performance in Schizophrenia
    Spiekermann, A.
    Schulz, M.
    Behrens, J.
    Driessen, M.
    Rahn, E.
    Beblo, T.
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2011, 79 (02) : 73 - 82
  • [50] Safety and effectiveness of lurasidone in the treatment of Chinese schizophrenia patients: An interim analysis of post-marketing surveillance
    Wei, Yu-Mei
    Wang, Xi-Jin
    Yang, Xiao-Dong
    Wang, Chuan-Sheng
    Wang, Li-Li
    Xu, Xiao-Ying
    Zhao, Gui-Jun
    Li, Bin
    Zhu, Dao-Min
    Wu, Qi
    Shen, Yi-Feng
    WORLD JOURNAL OF PSYCHIATRY, 2023, 13 (11): : 937 - 948
12345